Pablo Ortiz Romero, MD, PhD, University Complutense, Hospital 12 de Octubre, Medical School, Institute i+12, Madrid, Spain, shares his views on the future treatment landscape for cutaneous T-cell lymphoma (CTCL), highlighting the upcoming MOGAT trial (NCT04128072) of mogamulizumab in combination with total skin electron bean therapy (TSEB) in patients with stage IB-IIB CTCL. Prof. Romero also comment on novel therapies being explored for CTCL including ASTX660 and lacutamab. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.
Novel therapies on the horizon for CTCL
Теги
Speaker: Pablo Ortiz RomeroInstitution: University ComplutenseEvent: EORTC CLTF 2021Format: InterviewSubject: Cutaneous T-Cell LymphomaSubject: LymphomaSubject: Non-Hodgkin LymphomaMedicines: MogamulizumabMedicines: AntibodiesMedicines: LacutamabMedicines: ASTX660Field: TreatmentField: Immuno-OncologyFIeld: Trial UpdatesTrial: MOGATNCT04128072TSEBtotal skin electron beam therapyradiation therapy
![[Figh Mukhtasor Shoghir] SHOLAT WAJIB BESERTA WAKTU-WAKTUNA (1) || Habib Abdurrahman Hasan al Habsyi](https://i.ytimg.com/vi/uP7wGmOSB0M/mqdefault.jpg)
